Kelun-Biotech reported 1H26 total revenue of RMB978mn (+2.9% YoY), with pharmaceutical product sales contributing RMB657mn (+112% YoY), reaching 53% of our previous full-year estimate and coming in above our expectations. Management indicated that sac-TMT accounted for around 80% of product sales, underscoring a successful first half year of NRDL-driven commercialization: 2L+ TNBC and 3L EGFRm NSCLC entered the NRDL since Jan 2026, while we expect 2L EGFRm NSCLC and 2L+ HR+/HER2- BC indications to be included in NRDL by end-2026 and to drive further volume expansion. The accepted NDAs in 1L TNBC and 1L PD-L1-positive NSCLC should further broaden patient coverage upon approval. The Company swung to a net profit of RMB388mn in 1H26 (vs. a net loss of RMB145mn in 1H25), aided by lawsuit settlement income of RMB702mn.
MSD's upcoming sac-TMT data readouts and combo exploration serve as near-term catalysts. Sac-TMT is a cornerstone ADC asset for MSD, with 17 global Ph3 trials ongoing. The first readout — TroFuse-005 in 2L+ EC — met its dual primary endpoints of PFS and OS, and MSD plans to apply the Commissioner's National Priority Voucher (CNPV) toward the filing, potentially accelerating the asset's path to market. We expect further global Ph3 readouts in 2027, potentially including 3L+ GC, 3L EGFRm NSCLC and HR+/HER2- LA/mBC, followed by PD-L1-high NSCLC, 2L EGFRm NSCLC and 2L CC in 2028. Given the robust China data in the corresponding indications, we maintain a positive view on these readouts, which should provide strong support for valuation. Meanwhile, we believe MSD is exploring sac-TMT in combo with its PD-1/VEGF bsAb MK-2010. Further combination exploration by MSD (likely, in our view) would serve as an incremental catalyst. Kelun-Biotech also continues to collaborate with MSD on additional ADC assets, including SKB410 and SKB571.
Blockbuster potential further validated by China Ph3 wins. Following OptiTROP-Lung05's success in 1L PD-L1-positive NSCLC (PFS HR 0.35; OS HR 0.55 vs. pembrolizumab), the Ph3 Lung06 trial of sac-TMT plus pembrolizumab in 1L PD-L1-negative nsq-NSCLC also met its primary endpoint, supporting a China NDA and validating the ADC + IO paradigm across the full PD-L1 spectrum. Detailed Lung06 data are expected at ESMO, alongside TroFuse-005 (2L+ EC) and Breast03 (1L TNBC) readouts. In ADC + IO 2.0, Kelun-Biotech is advancing SKB118 (PD- 1/VEGF) plus sac-TMT in NSCLC, with expansion potential across indications and its broader ADC portfolio. Its next-generation ADC engine also continues to deliver, with dual-payload SKB565 (immuno-agonist + cytotoxin) and bispecific SKB103 (TAA/PD-L1) both entering clinical development.
Maintain BUY. We remain confident in sac-TMT's global development. Factoring in the positive China 1L NSCLC readouts across both PD-L1- positive and -negative settings, we raise the probability of success for its global trials and revise our DCF-based TP from HK$507.11 to HK$642.29 (WACC: 8.69%, terminal growth: 3.5%, unchanged).